Robert AbrahamMD, FRCPC



Phone: 902-473-5452
Fax: 902-473-6235
Mailing Address: 
QEII Health Sciences Centre, 1796 Summer Street, Halifax Infirmary Site, Diagnostic Imaging, 3rd Floor, Room 3316, PO BOX 9000, Halifax NS B3H 3A7
Research Topics:
  • – Development of x-ray imageable bland permanent microspheres
  • – Development of x-ray imageable Y-90 radioembolization microspheres for liver cancers
  • – CT based post therapy Y-90 Dosimetry using radiopaque Y-90 microspheres
  • – Retrospective Review - Imaging findings associated with ATV injuries
  • – Retrospective Review - Angioplasty of Fibrin Sheath for Malfunctioning Tunneled Dialysis Catheters
  • – Retrospective Quality Review - Y-90 Therapies at the QEII Hospital
  • – Evaluation of Y-90 Radioembolization practice patterns
  • – Evaluation of strategies to reduce patient anxiety in Interventional Radiology
  • – Interventional Radiology in Space Exploration
  • – Gender Discrepancy in Interventional Radiology
  • – Use of Epinephrine Auto-Injectors for Contrast Anaphylaxis in Radiology



  • Fellowship, (Interventional Radiology), Royal Melbourne Hospital
  • Residency, (FRCPC - Diagnostic Radiology), Dalhousie University
  • Medical internship, St. Paul’s Hospital, Vancouver
  • MD, Dalhousie University
  • BSc., (Chemistry), Dalhousie University


Dr. Robert (Bob) Abraham is a practicing clinician and interventional radiologist. His primary expertise is in endovascular treatment of liver cancer and vascular disease. Dr. Abraham's skills and experience cover all aspects of IR including minimally invasive cancer therapy (Y-90 radioembolization, chemoembolization and bland embolization), angioplasty/intravascular stenting for peripheral vascular disease, and endovascular treatment of complex thoracic and abdominal aortic aneurysms (fenestrated and branched stent graft deployment). He established the Uterine Fibroid Embolization program as well as the Y-90 Radioembolization program at the QEII Hospital.

Dr. Abraham co-founded ABK Biomedical Inc. and led ABK as CEO until August 2018 having raised over $12 million in equity investment and over $5 million in additional non-dilutive grant funding. ABK Biomedical is developing next generation imageable Y-90 radioembolization products and has a 6000 sq.ft. manufacturing and R&D facility and employs over 30 individuals. He continues to be active in the ongoing clinical research being conducted to demonstrate safety and efficacy of the innovative products being developed.  

Dr. Abraham has served as also Chief Examiner in Diagnostic Radiology at the Royal College of Physicians and Surgeons of Canada and as President of the Canadian Association for Interventional Radiology (CAIR) and his commitment to his field has been profiled in Interventional News.

Awards and honours:

  • Fellowship of Society of Interventional Radiology (FSIR), 2016
  • President Canadian Interventional Radiology Association (CIRA), 2014 to 2016
  • Program Chair, CIRA Annual Scientific Meeting, 2012 and 2013
  • Chief Examiner (Chair), Diagnostic Radiology, Royal College of Canada, 2010-2014
  • Chair, Oral Examination Committee, Royal College of Canada, 2005-2009
  • Research supported by multiple grants, totaling over $4 M